Ares Life Sciences to make second 2013 acquisition, the USA's Antigen Laboratories

15 April 2013

Ares Life Sciences has signed a definitive agreement to acquire 100% of the share capital of privately-held Planet Biopharmaceuticals, including its wholly owned subsidiary Antigen Laboratories, a producer of allergen extracts, which works closely with the ENT (ear, nose and throat) specialist community in the USA. Closing of the transaction, financial terms of which are not disclosed, is subject to certain closing conditions.

Ares Life Sciences, a Geneva, Switzerland-based health care investment firm established by the Bertarelli family, which sold its biotechnology business Serono to Germany’s Merck KGaA for $13.5 billion in 2006, recently signed an agreement to acquire Greer Laboratories, a leader in US allergy immunotherapy (AIT) market (The Pharma Letter March 8). Ares Life Sciences' portfolio currently also includes investments in Stallergenes, Euromedic and Esaote.

Strong growth potential for US AIT sector

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK